169 related articles for article (PubMed ID: 16750736)
1. Effects of dopamine and olprinone on ventricular energetics in sevoflurane-induced acute left ventricular depression in dogs.
Iwade M; Nomura M; Uezono S; Ashikari E; Ozaki M
J Cardiothorac Vasc Anesth; 2006 Jun; 20(3):358-63. PubMed ID: 16750736
[TBL] [Abstract][Full Text] [Related]
2. Different effects of olprinone on contractility in nonfatigued and fatigued diaphragm in dogs.
Fujii Y; Toyooka H
Can J Anaesth; 2000 Dec; 47(12):1243-8. PubMed ID: 11132748
[TBL] [Abstract][Full Text] [Related]
3. Effect of phosphodiesterase III inhibitor on contractility, afterload, and vascular capacitance during right heart bypass preparation.
Tanoue Y; Morita S; Nagano I; Ochiai Y; Tominaga R; Kawachi Y; Yasui H
Jpn J Thorac Cardiovasc Surg; 2001 Oct; 49(10):607-13. PubMed ID: 11692586
[TBL] [Abstract][Full Text] [Related]
4. Effects of a new cardiotonic phosphodiesterase III inhibitor, olprinone, on cardiohemodynamics and plasma hormones in conscious pigs with heart failure.
Adachi H; Tanaka H
J Cardiovasc Pharmacol; 1997 Jun; 29(6):763-71. PubMed ID: 9234657
[TBL] [Abstract][Full Text] [Related]
5. Effect of phosphodiesterase III inhibitor (Olprinone) on thoracic duct lymph flow in anesthetized sheep with experimentally induced heart failure by endothelin-1.
Tomoyasu M; Onizuka M; Inagaki M; Sato Y; Yamamoto T; Ishikawa S; Mitsui T
Lymphology; 2002 Dec; 35(4):144-52. PubMed ID: 12570323
[TBL] [Abstract][Full Text] [Related]
6. Effects of phosphodiesterase-III inhibitors on sevoflurane-induced impairment of rat diaphragmatic function.
Uesugi T; Mikawa K; Nishina K; Kodama SI; Obara H
Acta Anaesthesiol Scand; 2005 Jul; 49(6):819-26. PubMed ID: 15954966
[TBL] [Abstract][Full Text] [Related]
7. Effects of olprinone, a phosphodiesterase III inhibitor, on ischemic acute renal failure.
Anas C; Ozaki T; Maruyama S; Yamamoto T; Zu Gotoh M; Ono Y; Matsuo S
Int J Urol; 2007 Mar; 14(3):219-25. PubMed ID: 17430259
[TBL] [Abstract][Full Text] [Related]
8. The effects of the phosphodiesterase inhibitor olprinone on global cerebral ischemia.
Okayama N; Matsunaga A; Kakihana Y; Fujikawa K; Inoue K; Nagayama T; Takeyama M; Miyata A; Kanmura Y
Anesth Analg; 2010 Mar; 110(3):888-94. PubMed ID: 20042441
[TBL] [Abstract][Full Text] [Related]
9. Possible mechanisms underlying the vasodilatation induced by olprinone, a phosphodiesterase III inhibitor, in rabbit coronary artery.
Ohashi M; Dohi Y; Itoh T
Br J Pharmacol; 2000 Mar; 129(5):1000-6. PubMed ID: 10696101
[TBL] [Abstract][Full Text] [Related]
10. Hemodynamic effects of phosphodiesterase III inhibitor in patients with a large ventricular left-to-right shunt.
Momoi N; Sato M; Sato K; Sato T; Kobayashi T; Suzuki H; Suzuki H
Jpn Circ J; 2000 Apr; 64(4):249-53. PubMed ID: 10783045
[TBL] [Abstract][Full Text] [Related]
11. [Early hemodynamic effects of olprinone hydrochloride after coronary artery bypass grafting].
Marui A; Mochizuki T; Mitsui N; Koyama T; Horibe M
Jpn J Thorac Cardiovasc Surg; 1998 Nov; 46(11):1112-6. PubMed ID: 9884561
[TBL] [Abstract][Full Text] [Related]
12. Ventricular energetics after the Fontan operation: contractility-afterload mismatch.
Szabó G; Buhmann V; Graf A; Melnitschuk S; Bährle S; Vahl CF; Hagl S
J Thorac Cardiovasc Surg; 2003 May; 125(5):1061-9. PubMed ID: 12771880
[TBL] [Abstract][Full Text] [Related]
13. Cardiac and hemodynamic effects of intravenous R80122, a new phosphodiesterase III inhibitor, in a canine model of myocardial ischemia and heart failure.
Van de Water A; Xhonneux R; Reneman RS; Janssen PA
J Cardiovasc Pharmacol; 1992 Jul; 20(1):18-24. PubMed ID: 1383627
[TBL] [Abstract][Full Text] [Related]
14. Desflurane, sevoflurane, and isoflurane impair canine left ventricular-arterial coupling and mechanical efficiency.
Hettrick DA; Pagel PS; Warltier DC
Anesthesiology; 1996 Aug; 85(2):403-13. PubMed ID: 8712457
[TBL] [Abstract][Full Text] [Related]
15. Repetitive preischemic infusion of phosphodiesterase III inhibitor olprinone elicits cardioprotective effects in the failing heart after myocardial infarction.
Nomura Y; Horimoto H; Mieno S; Nakahara K; Okawa H; Yoshida M; Shinjiro S
Mol Cell Biochem; 2003 Jun; 248(1-2):179-84. PubMed ID: 12870671
[TBL] [Abstract][Full Text] [Related]
16. Synergic bronchodilator effects of a phosphodiesterase 3 inhibitor olprinone with a volatile anaesthetic sevoflurane in ovalbumin-sensitised guinea pigs.
Zhou J; Iwasaki S; Watanabe A; Yamakage M
Eur J Anaesthesiol; 2011 Jul; 28(7):519-24. PubMed ID: 21494151
[TBL] [Abstract][Full Text] [Related]
17. Effect of olprinone, a phosphodiesterase III inhibitor, on arterial wall distensibility: differentiation between aorta and common carotid artery.
Seki M; Mizushige K; Ueda T; Kitadai M; Matsuo H
Heart Vessels; 1999; 14(5):224-31. PubMed ID: 10830918
[TBL] [Abstract][Full Text] [Related]
18. Cardioprotection induced by olprinone, a phosphodiesterase III inhibitor, involves phosphatidylinositol-3-OH kinase-Akt and a mitochondrial permeability transition pore during early reperfusion.
Tosaka S; Makita T; Tosaka R; Maekawa T; Cho S; Hara T; Ureshino H; Sumikawa K
J Anesth; 2007; 21(2):176-80. PubMed ID: 17458647
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effects of amrinone, milrinone and olprinone in reversing bupivacaine-induced cardiovascular depression.
Hirabayashi Y; Igarashi T; Saitoh K; Fukuda H; Suzuki H; Shimizu R
Acta Anaesthesiol Scand; 2000 Oct; 44(9):1128-33. PubMed ID: 11028735
[TBL] [Abstract][Full Text] [Related]
20. Species-dependent pharmacodynamic effects of the selective low Km cyclic AMP phosphodiesterase III inhibitors WIN 58993 and WIN 62005.
Dundore RL; Pagani ED; Bode DC; Bacon ER; Singh B; Lesher GY; Buchholz RA; Silver PJ
J Cardiovasc Pharmacol; 1995 Jan; 25(1):14-21. PubMed ID: 7723343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
